Your browser doesn't support javascript.
loading
Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes.
Bérard, Anick; Sheehy, Odile; Kurzinger, Marie-Laure; Juhaeri, Juhaeri.
Afiliação
  • Bérard A; Research Center, CHU Ste-Justine, Montreal, Quebec, Canada; Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada. Electronic address: anick.berard@umontreal.ca.
  • Sheehy O; Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
  • Kurzinger ML; Sanofi, R&D, Global Pharmacovigilance and Epidemiology, Paris, France.
  • Juhaeri J; Sanofi, R&D, Global Pharmacovigilance and Epidemiology, Bridgewater, NJ.
J Allergy Clin Immunol ; 138(1): 97-104.e7, 2016 07.
Article em En | MEDLINE | ID: mdl-27045580
ABSTRACT

BACKGROUND:

Intranasal corticosteroid use during pregnancy has increased over the past decade.

OBJECTIVE:

We aim to estimate the safety of intranasal triamcinolone use during pregnancy, which was introduced for over-the-counter use in October 2013.

METHODS:

We designed a population-based prospective cohort study. From a cohort of 289,723 pregnancies in Montreal, Quebec, Canada, from 1998-2008, intranasal triamcinolone-exposed, other intranasal corticosteroid-exposed, and nonexposed women during the first trimester were studied for major congenital malformations (overall and organ specific) and spontaneous abortions and during the second/third trimesters for small-for-gestational age (SGA) newborns. The first trimester is the time window of interest for malformations and spontaneous abortion (organogenesis), and the second/third trimesters are the time windows of interest for SGA (fetal growth). Logistic regression model-based generalized estimating equations were used.

RESULTS:

Adjusting for potential confounders, use of intranasal triamcinolone during the first trimester of pregnancy was not significantly associated with the risk of overall congenital malformations (odds ratio [OR], 0.88; 95% CI, 0.60-1.28; 31 exposed cases) compared with nonexposure; however, it was associated with the risk of respiratory defects (OR, 2.71; 95% CI, 1.11-6.64; 5 exposed cases). Pregnancy exposure to intranasal triamcinolone was not significantly associated with the risk of spontaneous abortion (OR, 1.04; 95% CI, 0.76-1.43; 50 exposed cases). No association was found between second- or third-trimester exposure to intranasal triamcinolone and the risk of SGA (OR, 1.06; 95% CI, 0.79-1.43; 50 exposed cases).

CONCLUSIONS:

Maternal exposure to intranasal triamcinolone during pregnancy was not associated with the risk of SGA/spontaneous abortions/overall malformations. However, it has been shown to increase the risk of respiratory system defects. Chance finding cannot be ruled out.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triancinolona / Resultado da Gravidez / Exposição Materna / Vigilância em Saúde Pública / Glucocorticoides / Anti-Inflamatórios Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Pregnancy País/Região como assunto: America do norte Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Triancinolona / Resultado da Gravidez / Exposição Materna / Vigilância em Saúde Pública / Glucocorticoides / Anti-Inflamatórios Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Pregnancy País/Região como assunto: America do norte Idioma: En Revista: J Allergy Clin Immunol Ano de publicação: 2016 Tipo de documento: Article